Pathstone Family Office, LLC Nektar Therapeutics Transaction History

Pathstone Family Office, LLC

  • $15.6 Billion
  • Q3 2023

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.64 - $3.15 $3,153 - $15,520
-4,927 Reduced 25.81%
14,161 $9,000
Q4 2022

Oct 23, 2023
BUY
$2.03 - $4.28 $38,748 - $81,696
19,088 New
19,088 $43,000
Q4 2022

Feb 13, 2023
BUY
$2.03 - $4.28 $38,748 - $81,696
19,088 New
19,088 $43,000

Others Institutions Holding NKTR

# of Institutions
152
Shares Held
130M
Call Options Held
92.7K
Put Options Held
4.9K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $161M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email